Thalassaemia - chronic management & monitoring
thalassaemia mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Inherited defects of globin chain synthesis causing ineffective erythropoiesis and haemolysis. Transfusion-dependent thalassaemia requires regular transfusion plus iron chelation; non-transfusion-dependent forms need surveillance for iron loading and complications.
Red flags
- Cardiac iron overload with arrhythmia or heart failure
- Rapidly rising ferritin despite chelation
- Agranulocytosis on deferiprone
- New endocrine failure (diabetes, hypothyroidism)
- Post-splenectomy sepsis
Assessment
Differential diagnosis
- Iron deficiency anaemia
- Sickle cell / HbE disorders
- Congenital sideroblastic anaemia
- Other chronic haemolytic anaemia
- Myelodysplasia
Investigations
- FBC and film (microcytosis, target cells, basophilic stippling)
- Haemoglobin electrophoresis / HPLC and genetic analysis
- Ferritin, transferrin saturation
- Liver and cardiac iron by MRI (T2*) in transfusion-dependent disease
- Endocrine screen (thyroid, glucose, gonadal, parathyroid)
- Bone densitometry; echocardiography
Management
- Confirm genotype and classify as transfusion-dependent or non-transfusion-dependent
- For transfusion-dependent thalassaemia, transfuse regularly to maintain pre-transfusion Hb 95-105 g/L and suppress ineffective erythropoiesis
- Start iron chelation once iron loading established (after ~10-20 transfusions or ferritin rising)
- Select chelator (oral deferasirox or deferiprone, or subcutaneous desferrioxamine) and monitor cardiac/hepatic iron by MRI
- Give folic acid and avoid medicinal iron
- Screen for and manage endocrinopathy, osteoporosis, cardiac and hepatic complications
- Vaccinate and consider splenectomy only where clearly indicated (with prophylaxis)
- Offer luspatercept to reduce transfusion burden in eligible beta-thalassaemia
- Discuss curative options: allogeneic stem cell transplant and gene therapy
- Provide genetic counselling and antenatal screening for families
Drugs & doses
Deferasirox 14-28 mg/kg PO once daily (film-coated tablet)
Deferiprone 75-100 mg/kg/day PO in 3 divided doses
Desferrioxamine 20-40 mg/kg SC infusion over 8-12 h, 5-7 nights/week
Folic acid 5 mg PO once daily
Luspatercept 1-1.33 mg/kg SC every 3 weeks (transfusion-dependent beta-thalassaemia)
Disposition
Specialist thalassaemia centre; regular transfusion/chelation clinic and multidisciplinary surveillance.
Complications & pitfalls
- Iron-overload cardiomyopathy (leading cause of death)
- Hepatic fibrosis/cirrhosis
- Endocrinopathy and osteoporosis
- Extramedullary haematopoiesis
- Alloimmunisation and transfusion reactions
- Deferiprone agranulocytosis
Exam pearls
- Cardiac T2* MRI detects iron loading before symptoms and guides intensified chelation
- Pre-transfusion Hb target around 100 g/L suppresses marrow drive and extramedullary haematopoiesis
- Weekly FBC monitoring is essential on deferiprone (agranulocytosis risk)
- Never give oral iron to a thalassaemic patient
- Luspatercept and gene therapy are reshaping transfusion-dependent care
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.